Free
About
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02. This app is specifically intended for participants in the J3M-MC-JZQH study only.
Show more
What's New in J3M
5.4.1100
November 20, 2025
This update includes improvements and bug fixes to enhance your experience.
